28-Aug-2026
J&J granted China nod for oral psoriasis pill developed with Protagonist
Seeking Alpha News (Fri, 28-Aug 2:53 PM ET)
AbbVie Targets Rare Blood Disorder With New Phase 3 Etentamig Trial Plan
TipRanks (Fri, 28-Aug 12:31 PM ET)
AbbVie Expands Its IBD Pipeline With New Phase 2 Basket Trial in Crohn’s and Ulcerative Colitis
TipRanks (Fri, 28-Aug 12:31 PM ET)
AbbVie files for EMA approval of Skyrizi for Crohn’s disease treatment
Seeking Alpha News (Thu, 27-Aug 2:33 AM ET)
PRNewswire (Thu, 27-Aug 2:00 AM ET)
Eli Lilly shines as healthcare giants struggle on growth metrics
Seeking Alpha News (Tue, 25-Aug 9:18 AM ET)
AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
PRNewswire (Fri, 21-Aug 7:45 AM ET)
A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
Globe Newswire (Tue, 18-Aug 12:57 PM ET)
AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support
PRNewswire (Tue, 18-Aug 8:00 AM ET)
The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
Globe Newswire (Wed, 12-Aug 9:15 AM ET)
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
Abbvie trades on the NYSE stock market under the symbol ABBV.
As of August 28, 2026, ABBV stock price declined to $255.48 with 3,083,668 million shares trading.
ABBV has a beta of -0.58, meaning it tends to be less sensitive to market movements. ABBV has a correlation of 0.07 to the broad based SPY ETF.
ABBV has a market cap of $451.88 billion. This is considered a Mega Cap stock.
Last quarter Abbvie reported $17 billion in Revenue and $3.65 earnings per share. This beat revenue expectation by $230 million and missed earnings estimates by -$.12.
In the last 3 years, ABBV traded as high as $267.47 and as low as $135.85.
The top ETF exchange traded funds that ABBV belongs to (by Net Assets): VTI, VOO, IVV, SPY, VTV.
ABBV has outperformed the market in the last year with a price return of +26.1% while the SPY ETF gained +20.1%. ABBV has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +19.4% and +1.9%, respectively, while the SPY returned +2.8% and -1.1%, respectively.
ABBV support price is $254.23 and resistance is $262.07 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ABBV shares will trade within this expected range on the day.